Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drug research: marketing before evidence, sales before safety.

× No keyword cloud information.

8 in total

Review 1. Scope and impact of financial conflicts of interest in biomedical research: a systematic review.

Authors: Justin E Bekelman; Yan Li; Cary P Gross
Journal: JAMA Date: 2003 Jan 22-29 Impact factor: 56.272

2. Failing the public health--rofecoxib, Merck, and the FDA.

Authors: Eric J Topol
Journal: N Engl J Med Date: 2004-10-06 Impact factor: 91.245

3. The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.

Authors: Gisela Schott; Henry Pachl; Ulrich Limbach; Ursula Gundert-Remy; Wolf-Dieter Ludwig; Klaus Lieb
Journal: Dtsch Arztebl Int Date: 2010-04-23 Impact factor: 5.594

4. Setting the RECORD Straight.

Authors: Steven E Nissen
Journal: JAMA Date: 2010-03-24 Impact factor: 56.272

Review 5. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.

Authors: Stephan Heres; John Davis; Katja Maino; Elisabeth Jetzinger; Werner Kissling; Stefan Leucht
Journal: Am J Psychiatry Date: 2006-02 Impact factor: 18.112

6. [The German Clinical Trials Register: reasons, general and technical aspects, international integration].

Authors: G Dreier; H Hasselblatt; G Antes; M Schumacher
Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2009-04 Impact factor: 1.513

7. Undisclosed changes in outcomes in randomized controlled trials: an observational study.

Authors: Robert Ewart; Harald Lausen; Norman Millian
Journal: Ann Fam Med Date: 2009 Nov-Dec Impact factor: 5.166

8. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation.

Authors: Bruce M Psaty; Richard A Kronmal
Journal: JAMA Date: 2008-04-16 Impact factor: 56.272

8 in total

2 in total

1. [From the design of use study to the assessment of the benefit: with or without pharmaceutical industry?].

Authors: Franz Porzsolt
Journal: Med Klin (Munich) Date: 2011-01-16

2. Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.

Authors: Kenneth Blum; Marlene Oscar-Berman; Elizabeth Stuller; David Miller; John Giordano; Siobhan Morse; Lee McCormick; William B Downs; Roger L Waite; Debmalya Barh; Dennis Neal; Eric R Braverman; Raquel Lohmann; Joan Borsten; Mary Hauser; David Han; Yijun Liu; Manya Helman; Thomas Simpatico
Journal: J Addict Res Ther Date: 2012-11-27

2 in total